Lumito (LUMITO) investor relations material

Executive summary

• Transitioned to a clear market introduction phase for SCIZYS, with growing market interest and strengthened positioning in digital tissue analysis.

• Strategic partnerships established with Katana Labs and Atlas Antibodies to enhance product offering and market reach.

• SCIZYS technology included in offerings of Concept Life Sciences and Truly Labs, validating commercial relevance.

• Focused on user-driven evidence and application data to strengthen market position and drive adoption.

• Organization reinforced for commercial phase, including new Chief Business Officer and renewed ISO 13485 certification.

Financial highlights

• Q4 2025 net sales were 0 TSEK (79 TSEK in Q4 2024); full-year 2025 net sales were 0 TSEK (97 TSEK in 2024).

• Q4 2025 net loss after tax was -11,244 TSEK (-15,476 TSEK in Q4 2024); full-year net loss after tax was -43,940 TSEK (-41,564 TSEK in 2024).

• Cash flow from operating activities for Q4 was -8,616 TSEK (-8,713 TSEK); for the year, -25,110 TSEK (-31,017 TSEK).

• Cash and cash equivalents at year-end were 15,777 TSEK (21,592 TSEK at end 2024).

• New share issue raised 19,547 TSEK after costs; bridge loan of 2,000 TSEK repaid.

Outlook and guidance

• Entering 2026 with clear priorities, strengthened confidence, and focus on commercialization and partnerships.

• Continued emphasis on user-driven evidence, application development, and expanding market presence in Europe.